Salarius Pharmaceuticals, Inc. (SLRX)

USD 1.22

(-8.27%)

Market Cap (In USD)

1.75 Million

Revenue (In USD)

-

Net Income (In USD)

-12.54 Thousand

Avg. Volume

2.43 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.22-7.2
PE
-
EPS
-
Beta Value
0.932
ISIN
US79400X3052
CUSIP
79400X107
CIK
1615219
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David J. Arthur M.B.A.
Employee Count
-
Website
https://www.salariuspharma.com
Ipo Date
2015-01-29
Details
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.